A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis

被引：0
|
作者：
Wu, Y. [1 ]
Dong, X. [2 ]
Li, E. [1 ]
Fan, Y. [2 ]
Dong, D. [3 ]
Shi, Y. [3 ]
Wang, M. [4 ]
Yang, N. [4 ]
Ou, F. [4 ]
Wang, J. [4 ]
Yang, Y. [4 ]
机构：
[1] Xi An Jiao Tong Univ, Med Coll, Affiliated Hosp 1, Med Oncol Dept, Xian, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Oncol, Xian, Peoples R China
[3] Xi An Jiao Tong Univ, Med Oncol, Xian, Peoples R China
[4] Xi An Jiao Tong Univ, Med Oncol, Sch Med, Xian, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1678P
引用
收藏
页码：S920 / S920
页数：1
相关论文
共 50 条
  • [21] Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
    Su, Dan
    Jiao, Shun-Chang
    Wang, Li-Jie
    Shi, Wei-Wei
    Long, Yan-Yan
    Li, Juan
    Bai, Li
    TUMOR BIOLOGY, 2014, 35 (03) : 2313 - 2318
  • [22] A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma
    Byeon, Seonggyu
    Song, Haa-Na
    Kim, Hee Kyung
    Ham, Jun Soo
    Lee, Su Jin
    Lee, Jeeyun
    Park, Se Hoon
    CLINICAL SARCOMA RESEARCH, 2016, 6
  • [23] Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
    Riedl, Jakob M.
    Posch, Florian
    Horvath, Lena
    Gantschnigg, Antonia
    Renneberg, Felix
    Schwarzenbacher, Esther
    Moik, Florian
    Barth, Dominik A.
    Rossmann, Christopher H.
    Stotz, Michael
    Schaberl-Moser, Renate
    Pichler, Martin
    Stoger, Herbert
    Greil, Richard
    Djanani, Angela
    Schlick, Konstantin
    Gerger, Armin
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 3 - 13
  • [24] Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
    Umpawan, N.
    Termsinsuk, P.
    Kaosombatwattana, U.
    Akewanlop, C.
    Korphaisarn, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S919 - S920
  • [25] Real-World Outcomes of First-Line Chemotherapy in Metastatic Pancreatic Cancer: A Nationwide Population-Based Study in Korea
    Park, Chan Su
    Park, Byung Kyu
    Han, Joung-Ho
    Lee, Kyong Joo
    Son, Kang Ju
    CANCERS, 2024, 16 (18)
  • [26] Nineteen-year, real-world experience of first-line combination chemotherapy in patients with metastatic colorectal cancer: a propensity score analysis from southern Thailand
    Wonglhow, Jirapat
    Sathitruangsak, Chirawadee
    Dechaphunkul, Arunee
    Sunpaweravong, Patrapim
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (08)
  • [27] Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
    Yang, Zhenyun
    Wu, Weijie
    Hu, Zhiwen
    Fu, Yizhen
    Hu, Zili
    Pan, Yangxun
    Wang, Juncheng
    Chen, Jinbin
    Zhou, Zhongguo
    Zhang, Yaojun
    Chen, Minshan
    Hu, Dandan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Second-line chemotherapy in advanced pancreatic cancer: A retrospective, single-center analysis
    Herrmann, T.
    Jaeger, D.
    Stremmel, W.
    Herrmann, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study
    Woo, Sang Myung
    Lee, Woo Jin
    Han, Sung-Sik
    Park, Sang-Jae
    Kim, Tae Hyun
    Koh, Young Hwan
    Kim, Hyun Bum
    Hong, Eun Kyung
    Park, Joong-Won
    Kim, Chang-Min
    CHEMOTHERAPY, 2012, 58 (03) : 225 - 232
  • [30] A retrospective study of first-line combination chemotherapy in advanced colorectal cancer A Korean single-center experience.
    Lee, S.
    Park, J.
    Park, S.
    Kang, W.
    Lim, H.
    Park, Y.
    Park, K.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345